Particularly interesting for therapeutic purposes is the LpMab series recognizing cancer-specific aberrant glycosylated podoplanin, which reacts only with podoplanin expressed in tumors and not with podoplanin in normal cells [245,246,247]. Here, PDPN is linked to cancer.